Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies Nearly 60% of adolescents treated with ICOTYDE achieved completely clear skin at Week 52 in the ICONIC-LEAD study SPRING HOUSE, Pa., March 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies, which assessed the efficacy and safety of ICOTYDE™ (icotrokinra) in the treatment of patients with moderate-to-severe plaque psoriasis (PsO).

Johnson & Johnson shows relative strength with a bull flag breakout attempt, supported by key moving averages, signaling improving demand and potential upside toward higher Fibonacci extension targets.

One is a diversified healthcare giant with a vast product lineup and an impressive dividend program. The other is a niche leader with a lineup and pipeline that should help it perform well through 2046.

JNJ's Innovative Medicine unit eyes Q1 growth on key drug momentum, but biosimilar pressure and Stelara's decline may weigh on results.

Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1 Milestone is a testament to ten years of daratumumab experience and innovation, continuing to transform multiple myeloma care BEERSE, BELGIUM, March 27, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted approval for a Type II variation to the labelling for DARZALEX® (daratumumab) subcutaneous (SC) formulation. The label update enables patients living with multiple myeloma or their caregivers to administer daratumumab from the fifth dose, if determined to be appropriate by their healthcare professional and following proper training.1 This landmark decision makes daratumumab the first oncology injectable approved for self-administration in Europe.1 Offering greater flexibility in care With this label update, patients and their healthcare professionals can work together to decide the most suitable choice of administration.1 It applies to all ten therapeutic indications of daratumumab SC for multiple myeloma, smouldering multiple myeloma and light chain (AL) amyloidosis.

Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.

JNJ's rapid pipeline progress and new drug approvals in 2025 set the stage for stronger growth impact from its expanding portfolio in 2026.